Magnesium Supplementation for the Prevention of Supraventricular Arrhythmias

• Status: Completed
• Trial end date: 2017-09-15
• Target enrollment: 0
• Participant gender: All

Summary

The primary objective of this research is to determine whether oral magnesium supplementation in healthy, community-living individuals will be associated with reductions in the burden of arrhythmias in the upper chambers of the heart (supraventricular arrhythmias).

• Phase: Phase 2
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: University of Minnesota

Criteria

Inclusion Criteria:

• Age 55 and older

• Ability to speak English

• Availability to attend baseline and follow-up visit approximately 12 weeks after baseline

Exclusion Criteria:

• Prior history of heart disease (coronary heart disease, heart failure, atrial fibrillation), stroke, severe renal disease

• Use of type I and III antiarrhythmics or digoxin

• Current use of magnesium supplements

• Any prior history of allergy or intolerance to magnesium

• Prior history of inflammatory bowel disease or any severe gastrointestinal disorder